全文获取类型
收费全文 | 10628篇 |
免费 | 698篇 |
国内免费 | 40篇 |
专业分类
耳鼻咽喉 | 154篇 |
儿科学 | 222篇 |
妇产科学 | 271篇 |
基础医学 | 1561篇 |
口腔科学 | 117篇 |
临床医学 | 901篇 |
内科学 | 1887篇 |
皮肤病学 | 541篇 |
神经病学 | 750篇 |
特种医学 | 334篇 |
外科学 | 1720篇 |
综合类 | 137篇 |
一般理论 | 8篇 |
预防医学 | 800篇 |
眼科学 | 275篇 |
药学 | 662篇 |
中国医学 | 16篇 |
肿瘤学 | 1010篇 |
出版年
2022年 | 73篇 |
2021年 | 160篇 |
2020年 | 78篇 |
2019年 | 137篇 |
2018年 | 181篇 |
2017年 | 112篇 |
2016年 | 146篇 |
2015年 | 180篇 |
2014年 | 267篇 |
2013年 | 428篇 |
2012年 | 523篇 |
2011年 | 526篇 |
2010年 | 312篇 |
2009年 | 309篇 |
2008年 | 494篇 |
2007年 | 548篇 |
2006年 | 553篇 |
2005年 | 526篇 |
2004年 | 529篇 |
2003年 | 535篇 |
2002年 | 505篇 |
2001年 | 105篇 |
2000年 | 98篇 |
1999年 | 115篇 |
1998年 | 121篇 |
1997年 | 122篇 |
1996年 | 99篇 |
1995年 | 95篇 |
1994年 | 97篇 |
1993年 | 96篇 |
1992年 | 72篇 |
1991年 | 59篇 |
1990年 | 78篇 |
1989年 | 73篇 |
1988年 | 67篇 |
1987年 | 80篇 |
1986年 | 71篇 |
1985年 | 58篇 |
1984年 | 74篇 |
1983年 | 85篇 |
1982年 | 94篇 |
1981年 | 101篇 |
1980年 | 77篇 |
1979年 | 61篇 |
1978年 | 57篇 |
1977年 | 58篇 |
1975年 | 55篇 |
1933年 | 53篇 |
1932年 | 52篇 |
1922年 | 51篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
3.
Sebastian Mondaca Walid K. Chatila David Bates Jaclyn F. Hechtman Andrea Cercek Neil H. Segal Zsofia K. Stadler Anna M. Varghese Ritika Kundra Marinela Capanu Jinru Shia Nikolaus Schultz Leonard Saltz Rona Yaeger 《Clinical colorectal cancer》2019,18(1):e39-e52
Background
Treatment of advanced anal squamous cell cancer (SCC) is usually with the combination of cisplatin and 5-fluorouracil, which is associated with heterogeneous responses across patients and significant toxicity. We examined the safety and efficacy of a modified schedule, FOLFCIS (leucovorin, fluorouracil, and cisplatin), and performed an integrated clinical and genomic analysis of anal SCC.Patients and Methods
We reviewed all patients with advanced anal SCC receiving first-line FOLFCIS chemotherapy – essentially a FOLFOX (leucovorin, fluorouracil, and oxaliplatin) schedule with cisplatin substituted for oxaliplatin – in our institution between 2007 and 2017, and performed deep sequencing to identify genomic markers of response and key genomic drivers.Results
Fifty-three patients with advanced anal SCC (48 metastatic; 5 unresectable, locally advanced) received first-line FOLFCIS during this period; all were platinum-naive. The response rate was 48% (95% confidence interval [CI], 32.6%-63%). With a median follow-up of 41.6 months, progression-free survival and overall survival were 7.1 months (95% CI, 4.4-8.6 months) and 22.1 months (95% CI, 16.9-28.1 months), respectively. Among all patients with advanced anal SCC that underwent sequencing during the study period, the most frequent genomic alterations consisted of chromosome 3q amplification (51%) and mutations in PIK3CA (29%) and KMT2D (22%). No genomic alteration correlated with response to platinum-containing treatment. Although there were few cases, patients with human papillomavirus-negative anal SCC did not appear to benefit from FOLFCIS, and all harbored distinct genomic profiles with TP53, TERT promoter, and CDKN2A mutations.Conclusions
FOLFCIS appears effective and safe as first-line chemotherapy in patients with advanced anal SCC and represents an alternative treatment option for these patients. 相似文献4.
5.
6.
7.
8.
Matthew J Matasar Ellen K Ritchie Nathan Consedine Carol Magai Alfred I Neugut 《European journal of cancer prevention》2006,15(4):367-370
Despite significant improvements in the prognosis of acute promyelocytic leukemia brought about by therapeutic advances, understanding of the epidemiology of acute promyelocytic leukemia remains limited. Earlier reports have suggested that Hispanics may have an increased incidence of acute promyelocytic leukemia, but no systematic analysis of national data has yet been reported. We performed a retrospective cohort study, using data from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute from 1992-2001 in order to compare leukemia incidence rates as a function of race and ethnicity. We identified 709 cases of acute promyelocytic leukemia and analyzed incidence rates by race and sex. Hispanics were not found to have greater lifetime incidence rates than whites, with an incidence relative rate (IRR) of 0.86 that of whites (P=0.17). The age distribution among Hispanics was significantly different from non-Hispanic whites, with greater incidence rates for children ages 1-19 years (IRR=1.9, P=0.02) and adult ages 20-44 years (IRR=1.6, P=0.004). Blacks had lower lifetime incidence rates than non-Hispanic whites (IRR=0.75, P=0.04), Hispanics (IRR=0.64, P=0.007), and Asians (IRR=0.67, P=0.03). Asians did not differ from non-Hispanic whites in lifetime or age-specific incidence rates. These results indicate that while US Hispanics do not have greater lifetime incidence rates of acute promyelocytic leukemia, blacks have lower incidence rates of acute promyelocytic leukemia than Hispanics, non-Hispanic whites, and Asians. 相似文献
9.
Diastolic function in children and adolescents on dialysis and after kidney transplantation: an echocardiographic assessment 总被引:1,自引:1,他引:0
Thirty-seven children and adolescents on renal replacement therapy (11 on haemodialysis, 14 on continuous ambulatory peritoneal dialysis and 12 after renal transplantation) were studied by echocardiography, echo-Doppler and phonocardiography. Right and left ventricular (R/L V) diastolic functions were measured by transmitral and transtricuspid flow velocities and by LV isovolumic relaxation time (LVIRT). Thirty-seven age- and sex-matched healthy subjects served as controls. R/L V diastolic dysfunction was only observed in the dialysis patients. In these patients LVIRT was prolonged. LV and RV peak inflow velocities were increased both in early (E) and late (A) diastole with a reduction in the E/A ratios. This pattern of diastolic dysfunction is compatible with the combined effects of a hypercirculatory state (volume overload, anaemia, arteriovenous fistula) and an abnormality of cardiac relaxation. The transplant patients showed no major cardiac abnormalities. 相似文献
10.